The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
Next week at the American Society of Human Genetics annual meeting, LabCorp researchers plan to present results from almost 1,000 triplet pregnancies.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.
The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.
Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.